Article Details

Tempus and Geisinger receive Breakthrough Device Designation for AFib risk detection platform

Retrieved on: 2021-03-26 13:06:49

Tags for this article:

Click the tags to see associated articles and topics

Tempus and Geisinger receive Breakthrough Device Designation for AFib risk detection platform. View article details on hiswai:

Excerpt

Tempus, a leader in artificial intelligence and precision medicine, has ... For the study, data scientists and medical researchers used 1.6 million ECGs ...

Article found on: www.northcentralpa.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo